Early-stage study results suggest that a single shot of the company’s therapy, which works differently than GLP-1 medicines, ...

A study, which was published in The New England Journal of Medicine, found that tirzepatide (Zepbound) is more effective for ...

Shares of weight-loss drug developer Metsera gained as much as 25% on Monday after the company's experimental drug helped patients lose weight in a small, early-stage trial, showing potential for a ...

Novo Nordisk's popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases cause a serious eye condition ...

Excess body weight can raise the risk of certain cancers, leading researchers to wonder whether blockbuster drugs like Wegovy, Ozempic ...

THURSDAY, June 5, 2025 (HealthDay News) — More American teenagers now use the weight-loss drug Wegovy, as doctors and ...

A new report from health data firm Truveta shows there was 50 per cent increase in American teenagers using the weight-loss drug Wegovy, particularly those living with obesity.

I've been a Novo Nordisk bull for quite some time now, and I wouldn't be as spooked by the situation. Here's why. Novo Nordisk got a two-year-plus head start in the white-hot obesity drugs market, ...

A new study brings into focus the relationship between diabetic GLP-1 users and the elevated risk of age-related eye disease.

Orforglipron (pronounced or-for-GLIP-ron) might be a mouthful to say, but Indianapolis-based Eli Lilly and Co. sees this ...

NVO advances obesity pipeline with CagriSema and Amycretin while expanding through major deals amid rising competition.